AZN Astrazeneca Earnings and EPS analysis

EPS in 2026 (TTM): $7.12

Last Report Period Date: Sep 30, 2026

As of November 2026, according to Astrazeneca's latest financial report, the company's current EPS (TTM) is $7.12. In 2025, the company recorded an earnings per share (EPS) of $6.6, which represents an increase compared to its EPS of $4.54 in 2024. Astrazeneca's earnings per share for the quarterly report ending on Sep 30, 2026 was $2.02.

The annual EPS in 2025 was $6.6, an increase of 45.4% from $4.54 in 2024. For the quarter ending Sep 30, 2026, the EPS was $2.02, showing a 23.2% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of September 2026 is $7.12. In 2024, the annual EPS was $4.54, showing an increase of 18.2% from 2023.

Over the last 12 months, Astrazeneca has registered an EPS growth of 23.2% (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS growth rate of 46% per year over the past 3 years. Over the last 5 years, the company had an average EPS growth rate of 22%. A 10-year view shows that AZN has seen an average EPS growth of 11.5% per year.